Humberto Martínez Orozco

Dr. Humberto Martínez Orozco

Neurobiología del Desarrollo y Neurofisiología, Instituto de Neurobiología, Universidad Nacional Autónoma de México, Querétaro, Mexico
orcid
Postdoctoral Researcher

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 October 2024 in Brain Sciences
Verified
Journal Article
Open access
PDF file
AGANDRADE JESUS GUERRERO
ANDRADE JESUS GUERRERO
Humberto Martínez OrozcoHumberto Martínez Orozco
Humberto Martínez Orozco
MRMarcos Mauricio Villegas Rojas
Marcos Mauricio Villegas Rojas
ABAlberto Santiago Balmaseda
Alberto Santiago Balmaseda
KMKaren Michelle Delgado Minjares
Karen Michelle Delgado Minjares
Luis O. Soto-RojasLuis O. Soto-Rojas
Luis O. Soto-Rojas
Alzheimer’s disease (AD), the most prevalent neurodegenerative disorder and the leading cause of dementia worldwide, profoundly impacts health and quality of life. While cognitive impairments—such as memory loss, attention deficits, and disorientation—predominate in AD, motor symptoms, though common, remain underexplored. These motor symptoms, including gait disturbances, reduced cardiorespiratory fitness, muscle weakness, sarcopenia, and impaired balance, are often associated with advanced stages of AD and contribute to increased mortality. Emerging evidence, however, suggests that motor symptoms may be present in earlier stages and can serve as predictive markers for AD in older adults. Despite a limited understanding of the underlying mechanisms driving these motor symptoms, several key pathways have been identified, offering avenues for further investigation. This review provides an in-depth analysis of motor symptoms in AD, discussing its progression, potential mechanisms, and therapeutic strategies. Addressing motor symptoms alongside cognitive decline may enhance patient functionality, improve quality of life, and support more comprehensive disease management strategies.

11 April 2019 in ACS Chemical Neuroscience
Verified
Journal Article
Closed access
Humberto Martínez OrozcoHumberto Martínez Orozco
Humberto Martínez Orozco
LMLaura Mariño
Laura Mariño
AUAna Belén Uceda
Ana Belén Uceda
JOJoaquin Ortega-Castro
Joaquin Ortega-Castro
BVBartolomé Vilanova
Bartolomé Vilanova
AMAdrover Miquel
Adrover Miquel

15 October 2025 in Ageing Research Reviews
Verified
Journal Article
Open access
KLKaren León-Arcia
Karen León-Arcia
JAJesús Andrade-Guerrero
Jesús Andrade-Guerrero
Humberto Martínez OrozcoHumberto Martínez Orozco
Humberto Martínez Orozco
MVMarcos M. Villegas-Rojas
Marcos M. Villegas-Rojas
IPIsaac Pérez-Segura
Isaac Pérez-Segura
Luis O. Soto-RojasLuis O. Soto-Rojas
Luis O. Soto-Rojas
This systematic review investigates the timeline of Alzheimer's disease (AD)-like changes in the intracerebroventricular streptozotocin (ICV-STZ) rat model, a key tool for studying sporadic, non-genetic forms of AD. Following PRISMA guidelines, we analyzed 402 studies to characterize the progression of key pathological features, including cognitive deficits, insulin resistance, neurodegeneration, neuroinflammation, oxidative stress, tau pathology, amyloid aggregation, blood-brain barrier (BBB) dysfunction, and alterations in the gut-brain axis. Most studies used young male Wistar rats, revealing a sex and age bias. Results show cognitive impairment beginning within the first 24 h after ICV-STZ administration and persisting beyond 121 days, accompanied by early molecular changes, including disrupted insulin signaling, apoptosis (on day 1), and oxidative stress (on day 7). These events triggered a cascade of neuroinflammation, synaptic loss, tau hyperphosphorylation, amyloid plaque formation/accumulation, and neuronal death that closely resemble human AD. This work provides the first unified time-course of these alterations, confirming the model's ability to mimic the complexity of AD, while also identifying important gaps, such as its limited use of female and aged rats, underexplored areas like the BBB and gut-brain axis, and specific brain regions that require further investigation. The sporadic AD rat model induced by ICV-STZ serves as a powerful and versatile platform for dissecting the multifactorial nature of AD, identifying early biomarkers, and accelerating the development of targeted and disease-modifying therapies.

Verified
Journal Article
Open access
PDF file
Humberto Martínez OrozcoHumberto Martínez Orozco
Humberto Martínez Orozco
ABAlberto Bencomo-Martínez
Alberto Bencomo-Martínez
JMJuan Pablo Maya-Arteaga
Juan Pablo Maya-Arteaga
PAPedro Francisco Rubio de Anda
Pedro Francisco Rubio de Anda
FSFausto Sanabria
Fausto Sanabria
SDSofía Diaz-Cintra
Sofía Diaz-Cintra
The complexity of Alzheimer’s disease (AD) pathophysiology represents a significant challenge in the development of effective therapeutic agents for its treatment. CNEURO-201 (CN, also Amylovis-201) is a novel pharmaceutical agent with dual activity as an anti-amyloid-β (Aβ) agent and σ1 receptor agonist. CN exhibits great efficacy at very low doses, delaying cognitive impairment and alleviating Aβ load in animal models of AD. However, CN functions on other remains related to this pathology remain to be investigated. The present study sought to evaluate the effects of CN treatment at a dosage of 0.1 mg kg−1 (p.o) over an eight-week period in the 3xTg-AD mouse model. In silico studies, as well as biochemical and immunofluorescence assays, were conducted on brain tissue to investigate the CN effects on acetylcholine metabolism, redox system, and glial cell activation-related biomarkers in brain regions that are relevant for memory. The results demonstrated that CN effectively rescues cognitive impairment of 3xTg-AD mice by influencing glial activity to reduce existing Aβ plaques but also modulating acetylcholine metabolism and the enzymatic response of proteins involved in the redox system. Our outcomes reinforced the potential of CN in treating AD by acting on multiple pathways altered in this disease.

Verified
Journal Article
Open access
PDF file
NPNelly Jovana Pastén-Castrejón
Nelly Jovana Pastén-Castrejón
Humberto Martínez OrozcoHumberto Martínez Orozco
Humberto Martínez Orozco
GGGloria Yareli Gutiérrez-Silerio
Gloria Yareli Gutiérrez-Silerio
HHHebert Luis Hernández-Montiel
Hebert Luis Hernández-Montiel
JMJuan Pablo Maya-Arteaga
Juan Pablo Maya-Arteaga
SDSofía Diaz-Cintra
Sofía Diaz-Cintra
Alzheimer’s disease (AD) is characterized by the accumulation of amyloid-β (Aβ) and chronic neuroinflammation, with microglia playing a central role in its pathogenesis. Alterations in microglial metabolism have been proposed to contribute to AD-related inflammatory responses and reduced Aβ clearance, suggesting that thiamine-dependent pathways may be relevant in this context. Thiamine pyrophosphate (TPP), the active form of vitamin B1, is essential for glucose metabolism and mitochondrial function; however, its association with microglial changes in AD remains unclear. In this study, 9-month-old female triple-transgenic AD (3xTg-AD) mice and non-transgenic controls (NoTg) received TPP (2.0 mg/mL) or saline as a vehicle for six weeks via osmotic pumps. Nesting, a hippocampus-dependent behavioral test, as well analyses of Aβ burden, microglial morphology, and the expression of genes related to metabolic and immune pathways were evaluated. Differences in nesting behavior between experimental groups were observed, but TPP treatment was not associated with an evident change in 3xTg-AD mice. In the subiculum and CA1 regions of the hippocampus of female 3xTg-AD mice exposed to TPP, a lower Aβ burden was observed, and morphological variations in microglia were detected in both groups (3xTg-AD and NoTg). Additionally, in the brain of the TPP-treated group, some changes in mRNA gene expression were recorded. Together, these findings describe hippocampal microglial and amyloid profiles following TPP treatment in 3xTg-AD mice and provide a basis for further investigation of thiamine-dependent pathways in AD-related neuroinflammatory contexts.

2 June 2026 in Neurochemical Research
Verified
Journal Article
Open access
Humberto Martínez OrozcoHumberto Martínez Orozco
Humberto Martínez Orozco
LCLUIS ANTONIO REYES CASTRO
LUIS ANTONIO REYES CASTRO
CLConsuelo Lomas-Soria
Consuelo Lomas-Soria
MSMartha Silvia Solís‑Ortiz
Martha Silvia Solís‑Ortiz
SDSofía Diaz-Cintra
Sofía Diaz-Cintra
Memory processes are susceptible to impairment induced by excessive consumption of hypercaloric diets, particularly those rich in saturated fats and fructose. Such dietary patterns have been linked to disrupted neurotransmission in the prefrontal cortex (PFC), where the balance between excitation and inhibition depends on efficient glucose metabolism and the synthesis of neuroactive amino acids. However, the molecular mechanisms underlying these effects remain poorly understood. Here, male C57BL/6 mice were fed for 10 weeks with a control diet, a high-fat diet (HFD), a high-fructose diet (HFrD), or a combined high-fat/high-fructose diet (HFFrD). Their body weight gain and visceral adiposity were primarily driven by saturated fat intake, whereas hyperglycemia was observed across all diets. Also, we assessed metabolic outcomes, recognition memory, and PFC molecular profiles, including neuroactive amino acids (GABA, glutamate, glutamine, aspartate, alanine, glycine, and taurine) and the expression of genes related to glucose metabolism ( Slc2a1 , Pcx , G6pd , Gck , Pck1 , Irs2 ) and the glutamate/GABA–glutamine cycle ( Glul , Glud1 , Gad1 , Gad2 ). Behaviorally, HFFrD reduced locomotor activity and caused the most significant impairment in recognition memory. In the PFC, diet composition generated distinct amino acid profiles, revealing vulnerability of the glutamine–glutamate–GABA cycle to hypercaloric intake. Transcriptional responses were diet-specific, with consistent Gad1 upregulation and broader induction of glucose metabolism–related genes. Together, these findings demonstrate diet-dependent metabolic and neurochemical remodeling in the PFC and support a link between excessive fat and/or fructose intake with disrupted glutamine–glutamate homeostasis and memory deficits.